Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
AIDS and Behavior · 2024
DOI: 10.1007/s10461-024-04463-3 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift AIDS and Behavior, 2024. Verfasst von Marla J Husnik und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: HIV Infections, Pyrimidines, Contraceptive Devices, Female, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Product adherence is critical to obtaining objective estimates of efficacy of pre-exposure prophylactic interventions against HIV-1 infection. With imperfect adherence, intention-to-treat analyses assess the collective effects of complete, sub-optimal and non-adherence, providing a biased and attenuated estimate of the average causal effect of an intervention. Using data from the MTN-020/ASPIRE phase III trial evaluating HIV-1 efficacy of the dapivirine vaginal ring, we conducted per-protocol, and adherence-adjusted causal inference analyses using principal stratification and marginal structural models. We constructed two adherence cut offs of ≥ 0.9 mg (low cutoff) and > 4.0 mg (high cutoff) that represent drug released from the ring over a 28-day period. The HIV-1 efficacy estimate (95% CI) was 30.8% (3.6%, 50.3%) (P = 0.03) from the per-protocol analysis, and 53.6% (16.5%, 74.3%) (P = 0.01) among the highest predicted adherers from principal stratification analyses using the low cutoff. Marginal structural models produced efficacy estimates (95% CIs) ranging from 48.8 (21.8, 66.4) (P = 0.0019) to 56.5% (32.8%, 71.9%) (P = 0.0002). Application of adherence-adjusted causal inference methods are useful in interpreting HIV-1 efficacy in secondary analyses of PrEP clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, University of Washington, Seattle, WA, USA.
- Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Department of Global Health, University of Washington, Seattle, WA, USA.
- Department of Biostatistics, University of Washington, Seattle, WA, USA.
- Department of Medicine, The Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA.
- ASTRA Consulting, Kensington, CA, USA.
Förderung
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
Zitieren
APA
Husnik, M. J., Heffron, R., Hughes, J. P., Richardson, B., van der Straten, A., Palanee-Phillips, T., Soto-Torres, L., Singh, D., Mirembe, B. G., Livant, E., Gaffoor, Z., Mansoor, L. E., Siva, S. S., Dadabhai, S., Kiweewa, F. M., Baeten, J. M., & MTN-020/ASPIRE Study Team (2024). Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence. AIDS and Behavior. https://doi.org/10.1007/s10461-024-04463-3
Vancouver
Husnik MJ, Heffron R, Hughes JP, Richardson B, van der Straten A, Palanee-Phillips T, et al. Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence. AIDS and Behavior. 2024. doi:10.1007/s10461-024-04463-3
BibTeX
@article{Husnik2024,
author = {Husnik, Marla J and Heffron, Renee and Hughes, James P and Richardson, Barbra and van der Straten, Ariane and Palanee-Phillips, Thesla and Soto-Torres, Lydia and Singh, Devika and Mirembe, Brenda Gati and Livant, Edward and Gaffoor, Zakir and Mansoor, Leila E and Siva, Samantha S and Dadabhai, Sufia and Kiweewa, Flavia Matovu and Baeten, Jared M and MTN-020/ASPIRE Study Team, MTN-020/ASPIRE Study Team},
title = {Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence},
journal = {AIDS and Behavior},
year = {2024},
doi = {10.1007/s10461-024-04463-3}
}
EUVIMED